

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	Grant of a Security Interest in Grantor's (Debtor's) Ownership Rights to Grantee (Secured Party) (See Document for Details)

**CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
PRISM PHARAMCEUTICALS, INC.		05/16/2008	CORPORATION: DELAWARE

**RECEIVING PARTY DATA**

<b>Name:</b>	Paul Royalty Fund Holdings II
<b>Street Address:</b>	140 E. 45th Street, 44th Floor
<b>Internal Address:</b>	c/o Paul Capital Partners
<b>City:</b>	New York
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10017
<b>Entity Type:</b>	PARTNERSHIP: NEW YORK

**PROPERTY NUMBERS Total: 5**

Property Type	Number	Word Mark
Serial Number:	78635053	PRISM PHARMACEUTICALS
Serial Number:	78635067	PRISM PHARMACEUTICALS
Serial Number:	78910301	NEXTERONE
Serial Number:	78910312	PREXTA
Serial Number:	78910292	VIDERONE

**CORRESPONDENCE DATA**

**Fax Number:** (703)816-4100  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
**Phone:** 703-816-4057  
**Email:** wfg@nixonvan.com  
**Correspondent Name:** Willem F. Gadiano  
**Address Line 1:** Nixon & Vanderhye P.C.  
**Address Line 2:** 901 North Glebe Road, 11th Floor

CH \$140.00 78635053

Address Line 4: Arlington, VIRGINIA 22203

ATTORNEY DOCKET NUMBER: WFG-4379-20

NAME OF SUBMITTER: Willem F. Gadiano

Signature: /Willem F. Gadiano/

Date: 05/21/2008

Total Attachments: 2  
source=prismrec#page1.tif  
source=prismrec#page2.tif

**UCC FINANCING STATEMENT**

FOLLOW INSTRUCTIONS (front and back) CAREFULLY

DELAWARE DEPARTMENT OF STATE  
 U.C.C. FILING SECTION  
 FILED 12:35 PM 05/16/2008  
 INITIAL FILING # 2008 1701224

SRV: 080558587

A. NAME & PHONE OF CONTACT AT FILER [optional]

B. SEND ACKNOWLEDGMENT TO: (Name and Address)

Kathleen A. Johnson  
 CT Corporation -UCC  
 208 S. LaSalle Street, 814  
 Chicago, IL 60604

THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY

**1. DEBTOR'S EXACT FULL LEGAL NAME** - insert only one debtor name (1a or 1b) - do not abbreviate or combine names

1a. ORGANIZATION'S NAME  
**Prism Pharmaceuticals, Inc.**

OR

1b. INDIVIDUAL'S LAST NAME FIRST NAME MIDDLE NAME SUFFIX

1c. MAILING ADDRESS CITY STATE POSTAL CODE COUNTRY  
**1150 First Avenue, Suite 1050 King of Prussia PA 19406 U.S.**

1d. SEE INSTRUCTIONS ADD'L INFO RE ORGANIZATION DEBTOR 1e. TYPE OF ORGANIZATION **Corporation** 1f. JURISDICTION OF ORGANIZATION **Delaware** 1g. ORGANIZATIONAL ID #, if any **3616835**  NONE

**2. ADDITIONAL DEBTOR'S EXACT FULL LEGAL NAME** - insert only one debtor name (2a or 2b) - do not abbreviate or combine names

2a. ORGANIZATION'S NAME

OR

2b. INDIVIDUAL'S LAST NAME FIRST NAME MIDDLE NAME SUFFIX

2c. MAILING ADDRESS CITY STATE POSTAL CODE COUNTRY

2d. SEE INSTRUCTIONS ADD'L INFO RE ORGANIZATION DEBTOR 2e. TYPE OF ORGANIZATION 2f. JURISDICTION OF ORGANIZATION 2g. ORGANIZATIONAL ID #, if any  NONE

**3. SECURED PARTY'S NAME** (or NAME of TOTAL ASSIGNEE of ASSIGNOR(S)/P) - insert only one secured party name (3a or 3b)

3a. ORGANIZATION'S NAME  
**Paul Royalty Fund Holdings II**

OR

3b. INDIVIDUAL'S LAST NAME FIRST NAME MIDDLE NAME SUFFIX

3c. MAILING ADDRESS CITY STATE POSTAL CODE COUNTRY  
**c/o Paul Capital Partners, 140 E. 45th St, 44th Floor New York NY 10017 U.S.**

**4. This FINANCING STATEMENT covers the following collateral:**

All of the Debtor's right, title and interest in, to and under the following property, whether now or hereinafter existing or acquired, whether tangible or intangible and wherever the same may be located: (a) all Accounts; (b) all Chattel Paper; (c) all Deposit Accounts; (d) all Instruments; (e) all General Intangibles (including all Payment Intangibles and all patents, trademarks, copyrights and licenses); (f) all Goods (including Inventory and all Equipment); (g) all Investment Property; (h) all Supporting Obligations; (i) all Documents (including all warehouse receipts and bills of lading); (j) all Commercial Tort Claims; (k) all Fixtures; and (l) all Proceeds and products of any and all of the foregoing. Each item of collateral listed herein shall have the meaning as prescribed in Article 8 or Article 9 of the Uniform Commercial Code, it being the intention of the Debtor that the description of the collateral set forth above be construed to include the broadest possible range of assets or property described herein. (See Exhibit)

**5. ALTERNATIVE DESIGNATION** (if applicable): LESSEE/LESSOR CONSIGNEE/CONSIGNOR BAILEE/BAILOR SELLER/BUYER AS LIEN NON-UCC FILING

6. This FINANCING STATEMENT is to be filed (for record) (or recorded) in the REAL ESTATE RECORDS. Attach Addendum (if applicable) 7. Check to REQUEST SEARCH REPORT(S) on Debtor(S) (optional) All Debtors Debtor 1 Debtor 2

**8. OPTIONAL FILER REFERENCE DATA**

DE Secretary of State (057679-0041)

KAT 7243572 so-1

lpg

FILING OFFICE COPY — UCC FINANCING STATEMENT (FORM UCC1) (REV. 05/22/02)

DEUCC1PNAT - 12/17/2002 C T System Online

**EXHIBIT**

**IN-LICENSED PATENTS AND PATENT APPLICATIONS**

<b>Country</b>	<b>Patent Number</b>	<b>Application Number</b>
United States	6,869,939	10/139,620
Europe		3728598.8
Australia	2003234285	2003234285
Canada		2483774
Japan		2004-500775
Korea		1020047017639
WIPO (PCT)		PCT/US03/13250

**IN-LICENSED TRADEMARK**

<b>Country</b>	<b>Mark</b>	<b>Registration Number</b>	<b>Application Number</b>
United States	CAPTISOL-ENABLED	2767898	76/395460

**CORPORATE TRADEMARKS**

<b>Country</b>	<b>Mark</b>	<b>Registration Number</b>	<b>Application Number</b>
United States	PRISM PHARMACEUTICALS		78/635053
United States	PRISM PHARMACEUTICALS & Logo		78/635067
United States	NEXTERONE		78/910301
United States	PREXTA		78/910312
United States	VIDERONE		78/910292

1340131

**TRADEMARK**

**RECORDED: 05/21/2008**

**REEL: 003781 FRAME: 0114**